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The world is combating an ongoing COVID-19 pandemic with health-care systems, society
and economies impacted in an unprecedented way. It is unclear how many people have
contracted the causative coronavirus (SARS-CoV-2) unknowingly and are asymptomatic.
Therefore, reported COVID-19 cases do not reflect the true scale of outbreak. Here we
present the prevalence and distribution of antibodies to SARS-CoV-2 in a healthy adult
population of the Netherlands, which is a highly affected country, using a high-performance
immunoassay. Our results indicate that one month into the outbreak (i) the seroprevalence in
the Netherlands was 2.7% with substantial regional variation, (ii) the hardest-hit areas
showed a seroprevalence of up to 9.5%, (iii) the seroprevalence was sex-independent
throughout age groups (18–72 years), and (iv) antibodies were significantly more often
present in younger people (18–30 years). Our study provides vital information on the extent
of exposure to SARS-CoV-2 in a country where social distancing is in place.
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Coronavirus disease 2019 (COVID-19) is an emerginginfectious disease caused by the severe acute respiratorysyndrome coronavirus 2 (SARS-CoV-2). The disease was
first documented in humans in China in December 2019. The
virus has since spread globally by person-to-person transmission,
resulting in an ongoing pandemic impacting public health,
health-care systems, society and the economy across the world1–4.
Common clinical COVID-19 manifestations include fever,
cough, fatigue, expectoration, shortness of breath, dyspnoea and
muscle soreness5. The median incubation period is estimated to
be 5.1 days (95% CI, 4.5 to 5.8 days), and 97.5% of those who
develop symptoms will do so within 11.5 days (95% CI, 8.2 to
15.6 days) of infection6. While the majority of patients show only
mild or moderate symptoms, some progress to viral pneumonia,
acute respiratory distress syndrome (ARDS), systemic inflam-
matory response syndrome (SIRS), multiple organ failure (MOF)
and death.
As of 24 June 2020 more than 9.1 million laboratory-confirmed
COVID-19 cases have been reported, including 473,797 deaths,
affecting 215 countries and territories around the world4. The
reported COVID-19 cases do not reflect the true scale of out-
break7–11. In many countries lockdown strategies have been
implemented and social distancing is mandatory to reduce
person-to-person transmission, protecting citizens and mitigating
the impact on health-care systems including intensive care
capacities. Likely, social distancing measures will need to remain
in place until population-based immunity is achieved through
natural exposure to the virus (herd immunity) or until effective
vaccines or therapeutics become available12,13.
If immune responses to SARS-CoV-2 are similar when com-
pared to other coronaviruses, infected individuals may be less
susceptible to reinfection for months to years, reducing the risk of
severe COVID-19 and also limiting the possibility of spreading
the virus14,15. Infection-induced herd immunity might arise when
enough people become infected and develop antibodies to the
virus, in addition to people with non-antibody-mediated immu-
nity or with SARS-CoV-2 pre-existing immune reactivity16,17.
Above the herd immunity threshold (HIT), which represents a
minimum number of people in a community that would need to
be immune, the infection may no longer persist in the population.
According to basic models, the HIT of SARS-CoV-2 is estimated
at 50 to 67%18,19. This relies on simplified assumptions, such as
homogeneous population mixing and uniform sterilizing immu-
nity in recovered individuals across demographic groups, which
are unlikely to hold true. Nevertheless, the HIT provides an
indication of the minimum proportion of a population that would
need to be immune until herd immunity could be achieved in the
absence of a vaccine.
It is unclear how many people contract the virus unknowingly.
Assuming that antibodies to SARS-CoV-2 are produced by the
adaptive immune system in response to virus exposure, at least in
the vast majority of cases, serology-based tests for SARS-CoV-2
may be used to determine the extent of asymptomatic SARS-CoV-
2 infections and to monitor the COVID-19 pandemic. Highly
accurate immunoassays were not available until recently15,20,21.
Population-based serological studies as well as high-quality
data on SARS-CoV-2 antibody production in healthy individuals
are urgently needed to assess both the true extent of virus spread
and the presence of potential antibody-mediated protection
against SARS-CoV-2 at the community level. Using outbreak and
pre-outbreak samples, we studied the prevalence and distribution
of antibodies to SARS-CoV-2 under social distancing in a healthy
adult population of a highly affected country, one month into the
outbreak.
Here, we show a low SARS-CoV-2 seroprevalence in the early
COVID-19 epidemic in the Netherlands, demonstrating that (i)
the seroprevalence was 2.7% with substantial regional variation,
(ii) the hardest-hit areas showed a seroprevalence of up to 9.5%,
(iii) the seroprevalence was sex-independent throughout age
groups (18–72 years), and (iv) antibodies were significantly more
often present in younger people (18–30 years).
Results
Serological test results. In total 7,361 donations from regular
plasma donors were tested, of which 248 (3.4%) were initially
reactive and 230 (3.1%) were repeat reactive in the Wantai total
antibody assay. For 218/230 repeat reactive donors archived
material of a pre-outbreak donation was available for testing,
showing seroconversion in 188/218 donors (86%) and pre-
outbreak reactivity in 30/218 (14%); for 12 repeat reactive donors
no pre-outbreak samples were available. The 188 donors with
confirmed seroconversion and the 12 donors from whom no pre-
outbreak sample was available were considered seropositive in the
subsequent analyses. Positive IgM test results were found as fol-
lows: in 144/180 (80%) seroconverters (8 donors not tested); in 3/
28 (11%) donors with pre-outbreak reactivity (2 donors not tes-
ted); and in 8/12 (67%) donors from whom no pre-outbreak
sample was available.
Distribution of SARS-CoV-2 antibody signals. The distribution
of SARS-CoV-2 total antibody signals in positive donors (n=
230) and negative donors (n= 7,131) is shown in Fig. 1a. Details
about seroconversions and false-reactive test results can be found
in Supplementary Fig. 1. As a reference, the SARS-CoV-2 total
antibody signals in ex-COVID-19 patients donating convalescent
plasma (n= 153) are shown in Fig. 1b. These patients had a
documented PCR-positive test result, were at least 14 days fully
recovered from mild to severe COVID-19 symptoms and were
sampled in the study period. The distribution of SARS-CoV-2
total antibody signals in ex-COVID-19 patients was comparable,
but not identical, to regular plasma donors who seroconverted;
low-positive signals were found more often in regular plasma
donors than in ex-COVID-19 patients.
Seroprevalence by geographic region, sex and age group. Based
on demonstrated seroconversion, 188/7,361 (2.6%) donors have
been infected with SARS-CoV-2. If donors from whom no pre-
outbreak sample was available are included this number is 200/
7,361 (2.7%). The seroprevalence varied by geographic region.
Figure 2 shows the seroprevalence in the 26 municipal health
service regions of the Netherlands, demonstrating a north to
south gradient. Details about the seroprevalence by region, sex
and age group can be found in Supplementary Table 1. The
prevalence of antibodies to SARS-CoV-2 was not different for
men and women (2.70% vs 2.73%). Logistic regression and chi-
square analysis showed that the seroprevalence in donors aged
18–30 years was significantly higher than in other age groups
(4.2% vs 2.4%; p= 0.026; Table 1). No additional association with
sex or age group was found in the logistic regression model if the
data were corrected for region of residence.
Discussion
The world is facing unprecedented challenges with communities
and economies everywhere affected by the COVID-19 pandemic.
Social distancing and other public health measures are placing an
increasing psychological burden on people, resulting in an
increasing need for exit strategies22.
As the situation evolves, public health interventions sig-
nificantly lower the real-time reproduction number (Rt), which
estimates the average number of secondary cases one case pro-
duces in a population made up of both susceptible and non-
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susceptible hosts23. If person-to-person transmission is limited
and the Rt drops, the pandemic may be controlled on a popula-
tion level until an effective SARS-CoV-2 vaccine or pharmaco-
logical therapy for COVID-19 becomes available12,13.
Another way out may be acquiring natural herd immunity to
SARS-CoV-2 as an indirect protection conferred by immune
individuals to the susceptible ones in the population18,19,24. If
natural herd immunity to SARS-CoV-2 is attainable during the
pandemic, policy makers may take this into account as an exit
strategy option. The 2.7% seroprevalence found in our study
shows that, 1 month into the outbreak and more than 2 weeks
after social distancing and lockdown interventions were imple-
mented, the proportion of SARS-CoV-2 antibody-positive indi-
viduals in the population tested was far below the 50–67% HIT.
Without social distancing the chains of infection may resume
shortly, even in the hardest-hit areas with a seroprevalence of up
to 9.5%. Importantly, recently published population-based ser-
oprevalence studies in areas of other countries, using different
immunoassays and divergent methods of sampling, also show low
prevalences of antibodies to SARS-CoV-2, suggesting that
populations are likely to remain susceptible to the virus and
future waves of the outbreak are inevitable without a vaccine or
antiviral prophylaxis25–27.
Antibodies were significantly more often detected in younger
people (18–30 years), which might be related to age-dependent
social behaviours before social distancing was implemented. Our
study further indicates that the prevalence of antibodies to SARS-
CoV-2 is sex-independent throughout age groups (18–72 years)
and can vary substantially among areas in a country. The regional
variation in the Netherlands may be associated with the cele-
bration of Carnival, for which main events occurred in the south
and southeastern parts of the country during the last week of
February 2020, when social distancing and restrictions on public
events and gatherings were not in place yet. Of course, the study
only covers SARS-CoV-2 infections in the first month of the
outbreak, and the results cannot be extrapolated to children, non-
healthy adults and elderly aged >72 years.
Our study was performed in the early COVID-19 epidemic in
the Netherlands. The 2.7% seroprevalence in the population
tested demonstrates limited presence of potential antibody-
mediated immunity to SARS-CoV-2 at the time of the study.
Because antibodies to the virus may not be detected during the
first weeks post infection, it can be assumed that more people
were infected between 27 February 2020 (first Dutch COVID-19
case) and April 2020 (the moment of sampling). Therefore, the
presence of potential antibody-mediated immunity may have
been higher than 2.7%. Using the same assay, the SARS-CoV-2
seroprevalence in the Dutch donor population had increased to
5.9% (419/7,150) in May 202028. This indicates that the pro-
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Fig. 1 Distribution of SARS-CoV-2 antibody signals in regular blood plasma donors and in recovered COVID-19 patients donating convalescent
plasma; 1–15 April 2020. a Distribution of SARS-CoV-2 total antibody signals and SARS-CoV-2 IgM test results in regular blood plasma donors (n=
7,361). b Distribution of SARS-CoV-2 total antibody signals in recovered COVID-19 patients donating convalescent plasma (n= 153).
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Netherlands remained far below the 50–67% HIT during the first
months of the COVID-19 epidemic. Of course, acquiring herd
immunity may also depend on both SARS-CoV-2 pre-existing
immune reactivity and vaccine-induced herd immunity, when a
COVID-19 vaccine becomes available29.
To check for potential selection bias due to using regular
plasma donors as study subjects, we calculated the prevalence of
antibodies to anti-SARS-CoV-2 after correction for the number of
residents in the various municipal health regions and for the age
distribution of the Dutch general population (18–70 years).
Although the number of donations tested varied between the
municipal health regions from 0.83 to 8.27 per 10,000 inhabitants,
the weighted seroprevalence was 2.73%, which is identical to the
unadjusted seroprevalence. Similarly, the estimated weighted
seroprevalence of the Dutch general population (20–70 years) was
2.76%, indicating that differences in the age distribution of the
plasma donor population studied, compared with the Dutch
general population, had no significant impact on the study results.
Further, the observed regional variation in SARS-CoV-2 ser-
oprevalence matches well with the reported geographic variation
of both laboratory-confirmed and hospitalized COVID-19 cases
in the Netherlands30. We therefore consider the seroprevalence
found in a sample of the Dutch donor population as an important
indication of the seroprevalence in the general population of the
Netherlands, until more specific data becomes available.
The Wantai SARS-CoV-2 total antibody ELISA shows per-
formance characteristics superior to other immunoassays cur-
rently on the market31,32. We calculated a test specificity of 99.6%
using 282 pre-outbreak samples collected in March and April
2018 (validation data in Method section). In the seroprevalence
study we found false-reactive test results in 30/7361 (0.4%) sub-
jects. For these subjects, false reactivity was present before the
COVID-19 outbreak with stable OD/CO ratios over months
(Supplementary Fig. 1), indicating consistent non-specific reac-
tions or cross-reactivity with antibodies to common seasonal
coronaviruses (OC43, 229E, NL63, HKU1)33. It is unknown
whether this potential cross-reactivity provides cross-protection
against SARS-CoV-2 infection.
Of note, the positive predictive value (PPV) of a test depends
on the combination of test specificity and seroprevalence. In
our study, the PPV of the Wantai SARS-CoV-2 total antibody
ELISA was 99%, 88% and 72% in areas with a seroprevalence of
4–10%, 2–4% and <2%, respectively. Hence, the PPV increases
with the seroprevalence and will increase as the outbreak
proceeds. This phenomenon must be taken into account if
SARS-CoV-2 antibody testing would in the future be con-
sidered for diagnostic services and for reducing social distan-
cing measures.
Our study has several limitations. First, samples were collected
from regular plasma donors without further selection. Although
all subjects were healthy at the time of sampling and did not
report health issues in the 2 weeks before, they might have been
recovered from COVID-19 symptoms earlier. As a consequence,
the number of subjects enrolled in the study after full recovery
from COVID-19 symptoms is unknown. It is therefore not pos-
sible to specifically assign SARS-CoV-2 seroprevalence data and
total antibody signals to asymptomatic or symptomatic infections.
Second, donors who experience COVID-19 symptoms may not
recover within a few weeks, which might have resulted in self-
deferral and not showing up for plasma donation. Therefore,
donors who suffered from COVID-19 symptoms may be
underrepresented in the study. Third, donors who experienced
COVID-19 symptoms during the 2 weeks before sample collec-
tion were not eligible to donate plasma in accordance with Eur-
opean laws and guidelines34,35. They were not enrolled in the
study, resulting in a possible underestimation of the ser-
oprevalence in the donor population. Fourth, the test sensitivity
in PCR-confirmed COVID-19 patients, who were at least 14 days
fully recovered when sampled, was 98.7% (151/153 seropositive;
Fig. 1b). This demonstrates that antibodies to SARS-CoV-2 were
detected in nearly all COVID-19 patients after full recovery from
mild to severe symptoms. However, the test sensitivity in
asymptomatic cases is unknown and might be lower than in
symptomatic cases, which could have resulted in an under-
estimation of the seroprevalence in the donor population.
It is unclear whether the presence of SARS-CoV-2 antibodies
in blood reflects immunity, be it short term or long term15,33,36.
Recent studies found strong correlation between ELISA results
and virus neutralization37,38. Wu and colleagues studied the
levels and time course of neutralizing antibodies (nAbs) in 175
patients who experienced mild COVID-19 symptoms39. In those
patients nAbs were detected from days 10–15 after onset of
disease and remained thereafter. Interestingly, middle-aged and











Fig. 2 SARS-CoV-2 seroprevalence in the Dutch blood donor population
by municipal health service region; 1–15 April 2020. The map shows the
Netherlands divided into municipal health service regions. The backbone of
the map was provided by the Dutch Institute for Public Health and the
Environment.
Table 1 Prevalence of anti-SARS-CoV-2 antibodies in Dutch








18–30 52/1,251 (4.2%) 3.1–5.4%
31–40 22/882 (2.5%) 1.6–3.8%
41–50 31/1,354 (2.3%) 1.6–3.2%
51–60 48/2,132 (2.3%) 1.7–3.0%
61–72 47/1,742 (2.7%) 2.0–3.8%
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than younger patients. Ten patients had undetectable nAb titres
(ID50: <40) and two showed very high titres (ID50: 15,989 and
21,567). These findings indicate that antibodies to SARS-CoV-2
in asymptomatic individuals and in patients with only mild
symptoms may have limited neutralizing capacity. Like in other
infections, non-nAbs may play a significant role in decreasing
the viral load, e.g. via Fc receptor-mediated uptake in innate
cells, leading to partial or even total protection from reinfec-
tion40. Therefore, SARS-CoV-2 antibody-mediated immunity,
including the role and formation of nAbs and non-nAbs, needs
further research both to ascertain whether asymptomatic and
non-severe cases become immune to the virus and to assess the
relevance of SARS-CoV-2-specific antibodies for the develop-
ment of safe and effective (i) vaccines, (ii) treatment of COVID-
19 patients with convalescent plasma transfusions, and (iii)
plasma-derived medicinal products (anti-SARS-CoV-2 hyper-
immune globulins)12,13,19,41–43.
Gilbert and colleagues have proposed an exit strategy approach
in which at first only seropositive individuals, recovered from
SARS-CoV-2 infection, return to their normal lives44. When the
pandemic subsides, gradually younger low-risk people without
symptoms might follow. Such an approach would slowly build up
immunity in the population, mitigating the impact on health-care
systems and intensive care capacities and reducing the intensity of
future waves of the pandemic. This would make it possible to
reconcile the advantages of two opposing strategies that have
been proposed: the strategy of global containment of the popu-
lation, which is economically and socially costly, and the strategy
based on natural herd immunity, which potentially involves a
substantial human cost if done too fast. To put this approach in
context, we stress that the protective effect of SARS-CoV-2-
specific antibodies in blood is not yet known and that serology-
based tests in general come with important pitfalls until accurate
confirmatory testing is available15,33,36,45. An antibody testing-
based exit strategy could thus lead to a resurgence of community
spread of the virus.
In conclusion, the seroprevalence in the healthy adult popu-
lation shows no evidence of adequate antibody-mediated
immunity to SARS-CoV-2 on the country level, suggesting that
acquiring natural herd immunity is not a realistic COVID-19 exit
strategy in the short term. Downscaling public health interven-
tions, including social distancing, in the absence of population-
based immunity may significantly increase the Rt and fuel the
COVID-19 pandemic, possibly resulting in uncontrollable virus
spread. During the pandemic it is pivotal to continuously revisit
public health interventions and lockdown exit strategies using up-
to-date data on both community spread of SARS-CoV-2 and
immunity to the virus.
Methods
Setting. The Netherlands is the most densely populated country of Europe with
17.2 million human inhabitants (421 per square kilometre). The first Dutch case of
COVID-19 was reported on 27 February 2020. An outbreak ensued, culminating in
812, 5159, 9127 and 11,863 hospital admissions, and in 1868, 13,614, 28,153 and
49,914 PCR-confirmed COVID-19 cases including 64, 1173, 3134 and 6100
documented fatalities by 15 March, 1 April, 15 April and 24 June 2020, respec-
tively46. Social distancing and lockdown interventions were implemented nation-
wide on 15 March 2020, when all restaurants, cafés, bars, discotheques, coffeeshops,
musea, concert halls, theatres, sports clubs, saunas, sex clubs, universities, schools
and childcare centres were closed and specific restrictions on public events, gath-
erings, work and travel became mandatory47. The Dutch approach was comparable
to most other European countries and all public health measures were well
respected.
Subjects and sampling. We studied the plasma samples of 7361 regular blood
plasma donors from throughout the Netherlands, collected from 1 until 15 April
2020. Subjects were enrolled in the study if they were accepted for routine dona-
tion, without further selection and in accordance with European laws and
guidelines34,35. As a consequence, all subjects were healthy at the time of donation
and had not reported health issues in the 2 weeks before donation. Subjects were
defined by age (18–72 years), gender and zip code of the subject’s residence. All age
groups were well represented with a balanced distribution of male and female
subjects residing in all regions of the Netherlands.
Serological testing. Donor samples were screened for antibodies to SARS-CoV-2
using a SARS-CoV-2 total antibody ELISA (Wantai Biological Pharmacy Enter-
prise Co., Ltd., Beijing, China) following the manufacturer’s instructions. Samples
testing reactive (OD/CO ratio ≥ 1) were re-tested and considered positive if the re-
test was reactive. For the majority of positive donors an archived sample of a
donation from before the start of the COVID-19 outbreak was available and tested,
to determine seroconversion or false reactivity. For this purpose, seroconversion
was defined as transition from negative to positive with at least a two-fold increase
in OD/CO ratio. To study the consistency of false-reactive test results, archived
samples of multiple associated pre-outbreak donations were tested, if available.
Briefly, the Wantai ELISA used is a ‘double antigen sandwich assay’. This assay
format has the following advantages: the solid phase is coated with recombinant
SARS-CoV-2 antigens, which simultaneously bind antibody isotypes (IgA, IgM,
IgG) directed to SARS-CoV-2. For detection, a labelled SARS-CoV-2 antigen is
used. Additional testing of samples that were positive in the SARS-CoV-2 total
antibody ELISA was performed using a SARS-CoV-2 IgM ELISA (Wantai Biolo-
gical Pharmacy Enterprise Co., Ltd., Beijing, China) following the manufacturer’s
instructions.
Validation and evaluation. Performance characteristics of the Wantai SARS-CoV-
2 total antibody ELISA have been assessed in third-party evaluations, indicating a
sensitivity of 100% in PCR-confirmed COVID-19 cases (after 15–39 days following
the onset of symptoms; n= 90) and a specificity of 99.1% (n= 213) to 100% (n=
82)31,32. The performance of the Wantai ELISA, including positive and negative
predictive values, was superior compared to other assays32. We additionally vali-
dated the Wantai ELISA using panels of plasma and serum samples from (i) Dutch
blood donors collected in March and April 2018 (n= 282; 1/282 seropositive), (ii)
PCR-confirmed COVID-19 patients admitted to Dutch intensive care units in
March 2020 (n= 10; 9/10 seropositive; 1/10 seronegative), (iii) Dutch PCR-
confirmed COVID-19 patients with only mild symptoms (n= 11; 11/11 ser-
opositive), (iv) Dutch donors with a documented PCR-positive test result donating
convalescent plasma, who were at least 14 days fully recovered from mild to severe
COVID-19 symptoms (n= 153; 151/153 seropositive), and (v) patients with PCR-
positive test results for common HCoV, CMV or EBV infection (n= 40; 0/40
seropositive).
Data collection and analysis. Test results were obtained as described above. The
age, gender and zip code of residence of the individual subjects (both regular
plasma donors and recovered COVID-19 patients donating convalescent plasma)
were retrieved from the blood bank information system ePROGESA v5.0.3 (MAK-
SYSTEM International Group, France). Data were processed and analyzed using
Microsoft Office Access version 16.0 (Microsoft Corporation, USA). Association
between the prevalence of anti-SARS-CoV-2 antibodies and age, sex and region of
residence was assessed by logistic regression analysis using R v.3.5.2 (R Foundation,
Austria).
Ethics statement. Samples were collected only from voluntary, non-remunerated,
adult donors who provided written informed consent as part of routine donor
selection and blood collection procedures. The study was reviewed and approved
by the Ethics Advisory Council of Sanquin Blood Supply Foundation on March
27, 2020.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that all data supporting the findings of this study are available within
the paper and its supplementary information files. More detailed information on research
data is available from the corresponding authors upon reasonable request. Source data
are provided with this paper.
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